Immunomodulatory Effect of a Plasmid Expressing CD40 Ligand on DNA Vaccination Against Human Immunodeficiency Virus Type-1

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1999 Dec 3

PMID 10583605

Citations 7

Authors

A Ihata

S Watabe

S Sasaki

A Shirai

J Fukushima

K Hamajima

J Inoue

K Okuda

Affiliations

Soon will be listed here.

Abstract

CD40 ligand is a costimulatory molecule which acts a potent immunomodulator. We found the mice inoculated with human CD40 ligand expression plasmid (pMEhCD40L) combined with human immunodeficiency virus type-1 (HIV-1) DNA vaccine exhibited both humoral and cellular antigen-specific immunological enhancement. The expression of hCD40L induced predominantly antigen-specific immunoglobulin G (IgG) antibody response while it failed to induce mucosal IgA response. Delayed-type hypersensitivity (DTH) and cytotoxic T lymphocyte (CTL) activity were induced in a dose-dependent manner. Examination of the relative levels of the two IgG subclasses showed that co-injection of pMEhCD40L enhanced IgG2a response without suppressing IgG1 response. Similarly, the expression of pMEhCD40L enhanced not only T helper 1 (Th1)- but also Th2-type cytokine production. In conclusion, co-inoculation of pMEhCD40L with DNA vaccine was shown to be a useful way to enhance CTL responses without suppressing the humoral immune response in acquired immune deficiency syndrome (AIDS) patients.

Citing Articles

HIV DNA Vaccine: Stepwise Improvements Make a Difference.

Felber B, Valentin A, Rosati M, Bergamaschi C, Pavlakis G Vaccines (Basel). 2015; 2(2):354-79.

PMID: 26344623 PMC: 4494255. DOI: 10.3390/vaccines2020354.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai V, LaBranche C J Virol. 2014; 88(17):9579-89.

PMID: 24920805 PMC: 4136340. DOI: 10.1128/JVI.00975-14.

Human immunodeficiency virus and leishmaniasis.

Ezra N, Ochoa M, Craft N J Glob Infect Dis. 2010; 2(3):248-57.

PMID: 20927287 PMC: 2946682. DOI: 10.4103/0974-777X.68528.

Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity.

Lin F, Peng Y, Jones L, Verardi P, Yilma T J Virol. 2008; 83(3):1216-27.

PMID: 19036823 PMC: 2620918. DOI: 10.1128/JVI.01870-08.

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

Stone G, Barzee S, Snarsky V, Kee K, Spina C, Yu X J Virol. 2006; 80(4):1762-72.

PMID: 16439533 PMC: 1367159. DOI: 10.1128/JVI.80.4.1762-1772.2006.

References

Carmichael A, Jin X, Sissons P, Borysiewicz L . Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med. 1993; 177(2):249-56. PMC: 2190885. DOI: 10.1084/jem.177.2.249. View

Schoenberger S, Toes R, van der Voort E, Offringa R, Melief C . T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998; 393(6684):480-3. DOI: 10.1038/31002. View

Langlade-Demoyen P, Ngo-Giang-Huong N, Ferchal F, Oksenhendler E . Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J Clin Invest. 1994; 93(3):1293-7. PMC: 294083. DOI: 10.1172/JCI117085. View

Sallusto F, Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994; 179(4):1109-18. PMC: 2191432. DOI: 10.1084/jem.179.4.1109. View

Fanslow W, Clifford K, Seaman M, Alderson M, Spriggs M, Armitage R . Recombinant CD40 ligand exerts potent biologic effects on T cells. J Immunol. 1994; 152(9):4262-9. View

Okuda K, Kaneko T, Yamakawa T, Tanaka S, Shigematsu T, Yamamoto A . Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. J Mol Recognit. 1993; 6(3):101-9. DOI: 10.1002/jmr.300060302. View

Durie F, Foy T, Masters S, Laman J, Noelle R . The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today. 1994; 15(9):406-11. DOI: 10.1016/0167-5699(94)90269-0. View

Durie F, Foy T, Noelle R . The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease. Res Immunol. 1994; 145(3):200-5; discussion 244-9. DOI: 10.1016/s0923-2494(94)80184-3. View

Foy T, Durie F, Noelle R . The expansive role of CD40 and its ligand, gp39, in immunity. Semin Immunol. 1994; 6(5):259-66. DOI: 10.1006/smim.1994.1034. View

10.

Ulmer J, Deck R, DeWitt C, Friedman A, Donnelly J, Liu M . Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine. 1994; 12(16):1541-4. DOI: 10.1016/0264-410x(94)90081-7. View

11.

Han S, Hathcock K, Zheng B, Kepler T, Hodes R, Kelsoe G . Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J Immunol. 1995; 155(2):556-67. View

12.

Okuda K, Bukawa H, Hamajima K, Kawamoto S, Sekigawa K, Yamada Y . Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. AIDS Res Hum Retroviruses. 1995; 11(8):933-43. DOI: 10.1089/aid.1995.11.933. View

13.

Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S . HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med. 1995; 1(1):59-64. DOI: 10.1038/nm0195-59. View

14.

McDonnell W, Askari F . DNA vaccines. N Engl J Med. 1996; 334(1):42-5. DOI: 10.1056/NEJM199601043340110. View

15.

Liu M . Overview of DNA vaccines. Ann N Y Acad Sci. 1995; 772:15-20. DOI: 10.1111/j.1749-6632.1995.tb44727.x. View

16.

Yamamoto M, Vancott J, Okahashi N, Marinaro M, Kiyono H, Fujihashi K . The role of Th1 and Th2 cells for mucosal IgA responses. Ann N Y Acad Sci. 1996; 778:64-71. DOI: 10.1111/j.1749-6632.1996.tb21115.x. View

17.

Campbell K, Ovendale P, Kennedy M, Fanslow W, Reed S, Maliszewski C . CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity. 1996; 4(3):283-9. DOI: 10.1016/s1074-7613(00)80436-7. View

18.

Shirai A, Conover J, Klinman D . Increased activation and altered ratio of interferon-gamma: interleukin-4 secreting cells in MRL-lpr/lpr mice. Autoimmunity. 1995; 21(2):107-16. DOI: 10.3109/08916939508993357. View

19.

Choe J, Kim H, Zhang X, Armitage R, Choi Y . Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig down-regulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J Immunol. 1996; 157(3):1006-16. View

20.

Yang Y, Wilson J . CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996; 273(5283):1862-4. DOI: 10.1126/science.273.5283.1862. View